Answers are grounded in this paper and cite their sources.
The incidence of secondary malignancies following chemotherapy is progressively increasing, mostly due to prolonged survival of patients treated for primary cancer. So far, only 3 cases of solid cancer following busulphan administration have been reported. We describe the case of a patient who developed a renal cancer after 4 years of busulphan treatment for chronic myeloid leukemia. Immunosuppression rather than mutagenesis seems to be responsible for the emergence of second solid cancers in patients receiving busulphan.
No takes yet. Share an insight, caveat, or question.
Iurlo et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: